Jayachandra Babu Ramapuram

Prof. Jayachandra Babu Ramapuram

Auburn University, Harrison School of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RNRabin Neupane
Rabin Neupane
SBSai HS. Boddu
Sai HS. Boddu
Jwala RenukuntlaJwala Renukuntla
Jwala Renukuntla
Jayachandra Babu RamapuramJayachandra Babu Ramapuram
Jayachandra Babu Ramapuram
ATAmit K Tiwari
Amit K Tiwari
The transdermal route of drugs has received increased attention in recent years due to numerous advantages over the oral and injectable routes, such as avoidance of the hepatic metabolism, protection of drugs from the gastrointestinal tract, sustained drug delivery, and good patient compliance. The assessment of ex vivo permeation during the pharmaceutical development process helps in understanding the product quality and performance of a transdermal delivery system. Generally, excised human skin relevant to the application site or animal skin is recommended for ex vivo permeation studies. However, the limited availability of the human skin and ethical issues surrounding the use of animal skin rendered these models less attractive in the permeation study. In the last three decades, enormous efforts have been put into developing artificial membranes and 3D cultured human skin models as surrogates to the human skin. This manuscript provides an insight on the European Medicines Agency (EMA) guidelines for permeation studies and the parameters affected when using Franz diffusion cells in the permeation study. The need and possibilities for skin alternatives, such as artificially cultured human skin models, parallel artificial membrane permeability assays (PAMPA), and artificial membranes for penetration and permeation studies, are comprehensively discussed.

2 March 2021 in Cancer Reports
Verified
Journal Article
Open access
PDF file
MAManjusha Annaji
Manjusha Annaji
IPIshwor Poudel
Ishwor Poudel
SBSai H. S. Boddu
Sai H. S. Boddu
Robert ArnoldRobert Arnold
Robert Arnold
ATAmit K Tiwari
Amit K Tiwari
Jayachandra Babu RamapuramJayachandra Babu Ramapuram
Jayachandra Babu Ramapuram
Background: Resveratrol (3, 5, 4′‐trihydroxystilbene), a natural polyphenol and phytoalexin, has drawn considerable attention in the past decade due to its wide variety of therapeutic activities such as anticancer, anti‐inflammatory, and antioxidant properties. However, its poor water solubility, low chemical stability, and short biological half‐life limit its clinical utility.Recent findings: Nanoparticles overcome the limitations associated with conventional chemotherapeutic drugs, such as limited availability of drugs to the tumor tissues, high systemic exposures, and consequent toxicity to healthy tissues. This review focuses on the physicochemical properties of resveratrol, the therapeutic potential of resveratrol nano‐formulations, and the anticancer activity of resveratrol encapsulated nanoparticles on various malignancies such as skin, breast, prostate, colon, liver, ovarian, and lung cancers (focusing on both in vitro and in vivo studies).Conclusions: Nanotechnology approaches have been extensively utilized to achieve higher solubility, improved oral bioavailability, enhanced stability, and controlled release of resveratrol. The resveratrol nanoparticles have markedly enhanced its anticancer activity both in vitro and in vivo, thus considering it as a potential strategy to fight various cancers.

1 July 2018 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
HSHaley Shelley
Haley Shelley
Jayachandra Babu RamapuramJayachandra Babu Ramapuram
Jayachandra Babu Ramapuram

12 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
QWQi Wang
Qi Wang
KAKeerthi Atluri
Keerthi Atluri
ATAmit K Tiwari
Amit K Tiwari
Jayachandra Babu RamapuramJayachandra Babu Ramapuram
Jayachandra Babu Ramapuram
Various formulations of polymeric micelles, tiny spherical structures made of polymeric materials, are currently being investigated in preclinical and clinical settings for their potential as nanomedicines. They target specific tissues and prolong circulation in the body, making them promising cancer treatment options. This review focuses on the different types of polymeric materials available to synthesize micelles, as well as the different ways that micelles can be tailored to be responsive to different stimuli. The selection of stimuli-sensitive polymers used in micelle preparation is based on the specific conditions found in the tumor microenvironment. Additionally, clinical trends in using micelles to treat cancer are presented, including what happens to micelles after they are administered. Finally, various cancer drug delivery applications involving micelles are discussed along with their regulatory aspects and future outlooks. As part of this discussion, we will examine current research and development in this field. The challenges and barriers they may have to overcome before they can be widely adopted in clinics will also be discussed.

1 January 2016 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
DRDiane Render
Diane Render
TSTemesgen Samuel
Temesgen Samuel
HKHoward King
Howard King
MVMadan Vig
Madan Vig
SJShaik Jeelani
Shaik Jeelani
Vijaya RangariVijaya Rangari
Vijaya Rangari
Oral drug delivery systems provide the most convenient, noninvasive, readily acceptable alternatives to parenteral systems. In the current work, eggshell-derived calcium carbonate (CaCO3) nanoparticles were used to develop enteric drug delivery system in the form of tablets. CaCO3nanoparticles were manufactured using top-down ball-milling method and characterized by X-ray diffractometry (XRD) and transmission electron microscopy (TEM) and loaded with 5-fluorouracil as a model drug. Tablets with varying CaCO3core and binder compositions were fabricated and coated with Eudragit S100 or Eudragit L100. Suitability for enteric delivery of the tablets was tested by oral administration to rabbits and radiography. Radiograph images showed that the tablet remained in the stomach of the rabbit for up to 3 hours. Further modifications of these biomaterial-derived nanoparticles and the coatings will enable manufacturing of stable formulations for slow or controlled release of pharmaceuticals for enteric delivery.

26 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HAHamad Alrbyawi
Hamad Alrbyawi
IPIshwor Poudel
Ishwor Poudel
MAManjusha Annaji
Manjusha Annaji
SBSai HS. Boddu
Sai HS. Boddu
Robert ArnoldRobert Arnold
Robert Arnold
Jayachandra Babu RamapuramJayachandra Babu Ramapuram
Jayachandra Babu Ramapuram
Daunorubicin (DNR) was delivered using a pH-sensitive liposomal system in B16-BL6 melanoma cell lines for enhanced cytotoxic effects. DNR was encapsulated within liposomes and CL as a component of the lipid bilayer. PEGylated pH-sensitive liposomes, containing CL, were prepared in the molar ratio of 40:30:5:17:8 for DOPE/cholesterol/DSPE-mPEG (2000)/CL/SA using the lipid film hydration method and loaded with DNR (drug: lipid ratio of 1:5). The CL liposomes exhibited high drug encapsulation efficiency (>90%), a small size (~94 nm), narrow size distribution (polydispersity index ~0.16), and a rapid release profile at acidic pH (within 1 h). Furthermore, the CL liposomes exhibited 12.5- and 2.5-fold higher cytotoxicity compared to DNR or liposomes similar to DaunoXome®. This study provides a basis for developing DNR pH-sensitive liposomes for melanoma treatment.